Albena Zlatareva, Konstantin Tachkov, Milena Stoicheva, Svetla Georgieva, Georgi Momekov, Guenka Petrova^*

Show more
Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria.
Faculty of Public Health, Medical University of Sofia, Sofia, Bulgaria.
“Alexandrovska” Hospital, Medical University of Sofia, Sofia, Bulgaria.
Show less

Abstract: The absence of adequate national strategies for rare diseases (RD), high medicines prices and insufficient experts’ knowledge creates to the barriers in therapy, as well as the added factors of inappropriate diagnostics and difficulties in peoples’ access to health care. A heavier burden is placed on patients’ physical, mental, psychological and intellectual wellbeing as well as on the financial capabilities of the third party payers. This study aims to analyze the financial flow for RD therapy as part of the health insurance budget and regional differences in their financing. The point of view is that of the third party payer for a 4-year period. The study is a macro costing top down financial analysis of the expenditures for medicines for rare diseases spent by the 3rd party payer, in Bulgaria that is the national health insurance fund (NHIF). Applied were financial and statistical analyses towards the budget data for expenditures for pharmaceuticals at national and regional level. Results show a constant rise in healthcare medicines expenditures, including those for rare diseases therapy from 20 to 27 million �for a three-year period but it is not above 10% from the budget for medicines due to regulatory restrictions. A variety of deviations exist among regional counties, accounting for more than 50% differences in payment per diagnosis. This could be explained with insufficient knowledge and lack of therapeutic standards. There is a need for collaboration on a European level and the creation of a global fund to be able to satisfy therapeutic needs. A closer look at national differences and regional therapy is necessary, as well as standardization of health care services for better health care expenditures management.

Keywords: Healthcare Budget, Medicines Budget, Rare Diseases, Orphan Medicines

Cite this paper: Zlatareva, A. , Tachkov, K. , Stoicheva, M. , Georgieva, S. , Momekov, G. and Petrova, G. (2014) Financial Analysis of the Access to Pharmacotherapy for Rare Diseases in Bulgaria. Modern Economy, 5, 461-467. doi: 10.4236/me.2014.55044.

References

[1]   EC (2007) Rare Diseases Challenge for the Society.
www.ec.europa.eu/health/archive/ph_threats/non_com/docs/raredis_comm_bg.pdf

[2]   European Parliament and EC. Decision No. 1295/1999/ЕU from 29 April 1999 for the Acceptance of Actions of the Community for Rare Diseases Prophylactics within the Context of the Public Health Activities; ОВ L 155, 22.6.1999, page 1; Changed with Decision No. 1786/2002/ЕU (ОВ L 271, 9.10.2002).

[3]   Orphanet (2010) Prevalence of Rare Diseases in Bulgaria.
http://www.medicine.bg/novini/nad-polovin-milion-balgari-stradat-ot-redki-bolesti

[4]   Ministry of Health National Program for Rare Diseases (2012)
www.rare-bg.com/wp-content/uploads/2013/01/NPRD_2009-20131.doc

[5]   Schey, C., Milanova, T. and Hutchings, A. (2011) Estimating the Budget Impact of Orphan Medicines in Europe: 2010-2020. Orphanet Journal of Rare Diseases, 27, 62.
http://dx.doi.org/10.1186/1750-1172-6-62

[6]   Kamusheva, M., Stoimenova, A., Doneva, M., Zlatareva, A. and Petrova, G. (2013) A Cross Country Comparison of Reimbursed Orphan Medicines in Bulgaria, Greece, Macedonia. Biotechnology and Biotechnology Equipment, 27, 4186-4193.
http://dx.doi.org/10.5504/BBEQ.2013.0066

[7]   Zlatareva, A., Lakic, D., Kamusheva, M., Spaskov, D., Georgi, M. and Guenka, P. (2013) Analysis of Access to Orphan Drugs in Five Neighboring European Countries—Bulgaria, Greece, Macedonia, Romania and Serbia. World Journal of Pharmacy and Pharmaceutical Sciences, 2, 4415-4434.

[8]   Savova, A., Kamusheva, M., Georgieva, S., Stoimenova, A. and Petrova, G. (2013) Budget Impact Analysis of Chronic Myeloid Leukemia Treatment in Bulgaria. Biotechnology and Biotechnology Equipment, 27, 3595-3598.
http://dx.doi.org/10.5504/BBEQ.2012.0075

[9]   Inotai, A., Petrova, G., Vitezic, D. and Kaló, Z. (2014) Benefits of Investment into Modern Medicines in Central-Eastern European Countries. Experts Review of Pharmacoeconomics and Outcomes Research, 14, 71-79.
http://dx.doi.org/10.1586/14737167.2014.868314

[10]   INFOPACK (2010) Patient Care, a Public Affair. EURORDIS, European Union.
http://download.rarediseaseday.org/Rare%20Disease%20Day%20Info%20pack%202009.pdf

[11]   MH (2009) National Council for Rare Diseases. National Program for Rare Diseases for the Period.
http://www.mh.government.bg/Articles.aspx?lang=bg-BG&

[12]   Bignami, F. (2007) Eurordis Survey on Orphan Drugs Availability in Europe. Presented at the 6th Eurordis Round Table of Companies Workshop, Barcelona.
http://www.eurordis.org/IMG/pdf/2007ODsurvey-eurordis.pdf

[13]   Simoens, S. (2011) Pricing and Reimbursement of Orphan Drugs: The Need for More Transparency. Orphanet Journal of Rare Diseases, 6, 42.
http://dx.doi.org/10.1186/1750-1172-6-42